Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2023

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions/special resolution by way of poll at the Annual General Meeting.

The board of directors (the "Board") of Ocumension Therapeutics (the "Company") is pleased to announce the poll results of the annual general meeting of the Company (the "Annual General Meeting") held at 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai, PRC on Friday, June 16, 2023 at 10:00 a.m.

Reference is made to the Company's circular (the "Circular") in connection with the Annual General Meeting and notice of the Annual General Meeting (the "Notice") dated April 26, 2023. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

	Ordinary Pagalutions			Number of Votes (%)	
			Ordinary Resolutions	For	Against
1.	Com	receive and adopt the audited consolidated financial statements of the pany and its subsidiaries and the reports of the Directors and auditor (100.000000%) the year ended December 31, 2022.			0 (0.000000%)
2.	(a)	To re-elect the following retiring Directors:			
		(i)	Mr. Ye LIU as an executive Director	483,789,355 (100.000000%)	1 (0.000000%)
		(ii)	Ms. Yumeng WANG as a non-executive Director	483,664,355 (99.974162%)	125,001 (0.025838%)
		(iii)	Mr. Ting Yuk Anthony WU as an independent non-executive Director	406,164,980 (83.954923%)	77,624,375 (16.045077%)
	(b)	To authorize the Board of the Company to fix the remuneration of the Directors.		483,745,236 (99.990880%)	44,120 (0.009120%)
3.		re-appoint Deloitte Touche Tohmatsu as the auditor of the Company authorize the Board to fix their remuneration. 483,789,356 (100.000000%)		0 (0.000000%)	
4.	(A)	with	ive a general mandate to the Directors to allot, issue and deal additional shares not exceeding 20% of the issued share capital e Company as of the date of this resolution.	421,767,820 (87.180054%)	62,021,536 (12.819946%)
	(B)	excee	ive a general mandate to the Directors to repurchase shares not eding 10% of the issued share capital of the Company as of the of this resolution.	483,789,356 (100.000000%)	0 (0.000000%)
	(C)	resol capit	xtend the authority given to the Directors pursuant to ordinary ution no. 4(A) to issue shares by adding to the issued share al of the Company the number of shares repurchased under tary resolution no. 4(B).	406,731,820 (84.072089%)	77,057,536 (15.927911%)

As more than 50% of the votes were cast in favor of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.

	Special Desclution	Number of Votes (%)	
	Special Resolution	Special Resolution For	
5.	To approve the adoption of the New M&A in substitution for and to the exclusion of the Existing M&A.	483,789,356 (100.000000%)	0 (0.000000%)

As not less than 75% of the votes were cast in favor of the above resolution, it was passed as a special resolution at the Annual General Meeting.

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

The total number of issued Shares as of the date of the Annual General Meeting was 690,711,280 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. There were no Shares entitling the holders to attend and abstain from voting in favor at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting. No Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Annual General Meeting.

The executive Directors, Mr. Ye LIU and Dr. Zhaopeng HU, the non-executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI and Ms. Yumeng WANG and the independent non-executive Directors, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG attended the Annual General Meeting, either in person or by means of telecommunication.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 16, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.